Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 4 de 4
Filter
Add more filters










Database
Language
Publication year range
1.
Diabetes Obes Metab ; 15(4): 324-34, 2013 Apr.
Article in English | MEDLINE | ID: mdl-23121319

ABSTRACT

AIMS: Intensive glycaemic control in type 2 diabetes achieved by insulin is generally accompanied by body weight gain. This study was performed to emphasize the meaning of caloric analysis of urine and faeces for energy balance. METHODS: We measured energetic loss via urine and faeces during antihyperglycaemic treatment in male obese Zucker diabetic fatty (ZDF) rats. Rats were treated for 10 days with the sodium-glucose-linked transporter-2 (SGLT2) inhibitor AVE2268, with insulin glargine, with the GLP-1 receptor agonist lixisenatide and with the combination of insulin glargine and lixisenatide. Each study was accompanied by one lean (Fa/?) and one obese (fa/fa) untreated non-diabetic and diabetic control group, respectively. Blood glucose, body weight alterations and food assimilation efficiency were monitored. RESULTS: In control ZDF rats, more than 12 g/day of pure glucose was urinarily excreted. In total, the energetic loss via urine exceeded 30% from total energy uptake. Insulin glargine treatment decreased urinary energetic loss, leading to a body weight gain of approximately 3 g/day. An almost body weight-neutral antihyperglycaemic treatment could be achieved with AVE2268 and lixisenatide. While lixisenatide reduced body weight gain via reduction of energy uptake, the SGLT2 inhibitor even increased urinary glucose and thus energy excretion. Combining insulin glargine with lixisenatide attenuated the anabolic effect of insulin resulting in weight neutrality. CONCLUSIONS: Our data clearly show renal contribution to the body's energy control by urinary glucose excretion (UGE) during antidiabetic treatment. The undesired retained energy could be reduced via additional UGE or via simultaneous reduction of energy uptake and/or energy retention.


Subject(s)
Diabetes Mellitus, Experimental/drug therapy , Diabetes Mellitus, Experimental/metabolism , Diabetes Mellitus, Type 2/drug therapy , Diabetes Mellitus, Type 2/metabolism , Glucosides/pharmacology , Hypoglycemic Agents/pharmacology , Insulin, Long-Acting/pharmacology , Peptides/pharmacology , Animals , Blood Glucose/drug effects , Glucagon-Like Peptide-1 Receptor , Glycated Hemoglobin/drug effects , Insulin Glargine , Kidney/drug effects , Male , Rats , Rats, Zucker , Receptors, Glucagon/agonists , Sodium-Glucose Transporter 2 , Sodium-Glucose Transporter 2 Inhibitors , Weight Gain/drug effects
2.
Lab Anim ; 46(1): 32-9, 2012 Jan.
Article in English | MEDLINE | ID: mdl-22087029

ABSTRACT

Male obese Zucker Diabetic Fatty (ZDF) rats develop type 2 diabetes around eight weeks of age, and are widely used as a model for human diabetes and its complications. The objective of the study was to test whether the complications manifested in the kidney and nerves of ZDF rats really correspond to human diabetic complications in their being related to the hyperglycaemic state. Four groups of ZDF rats were used. One lean (Fa/?) and one obese (fa/fa) untreated group served as non-diabetic and diabetic controls. In two further groups of obese (fa/fa) rats, diabetes was prevented by pioglitazone or delayed by food restriction. All rats were monitored up to 35 weeks of age with respect to their blood glucose, HbA1c and insulin levels, their kidney function (urinary glucose excretion, renal glucose filtration, glomerular filtration rate, albumin/creatinine ratio), and their nerve function (tactile and thermal sensory threshold and nerve conduction velocity). Pioglitazone prevented the development of diabetes, while food restriction delayed its onset for 8-10 weeks. Accordingly, kidney function parameters were similar to lean non-diabetic rats in pioglitazone-treated rats and significantly improved in food-restricted rats compared with obese controls. Kidney histology paralleled the functional results. By contrast, nerve functional evaluations did not mirror the differing blood glucose levels. We conclude that the ZDF rat is a good model for diabetic nephropathy, while alterations in nerve functions were not diabetes-related.


Subject(s)
Diabetes Mellitus, Type 2/complications , Diabetic Nephropathies/etiology , Diabetic Neuropathies/etiology , Animals , Blood Chemical Analysis , Caloric Restriction , Diabetes Mellitus, Type 2/drug therapy , Diabetic Nephropathies/drug therapy , Diabetic Neuropathies/drug therapy , Disease Models, Animal , Enzyme-Linked Immunosorbent Assay , Humans , Hyperglycemia/complications , Hyperglycemia/drug therapy , Hypoglycemic Agents/administration & dosage , Kidney/pathology , Kidney Function Tests , Male , Neural Conduction , Pioglitazone , Rats , Rats, Zucker , Sensory Thresholds , Thiazolidinediones/administration & dosage
4.
Oecologia ; 119(4): 484-492, 1999 Jun.
Article in English | MEDLINE | ID: mdl-28307706

ABSTRACT

Two species of the genus Acomys coexist in arid zones of southern Israel. Acomys russatus is distributed in extremely arid areas, while A. cahirinus is common in both Mediterranean and arid regions. Individuals of both species from a rodent community in the Ein Gedi Nature Reserve were implanted with temperature-sensitive transmitters. Body temperature (T b) rhythms were recorded in free-ranging mice at four different seasons of the year. A. cahirinus (30-45 g) showed a nocturnal rhythm of T b throughout the year. In the activity phase during the night T b increased to 38.2°C. During the day T b decreased to 34°C. This species displayed this pattern in summer also when ambient temperatures rose above T b. The T b of A. russatus (45-65 g) varied between 34.8 and 41°C during the hot season, showing a bimodal temperature rhythm with maximal values in the morning and in the evening. Measurements of activity in this species showed inactivity during the hottest period of a summer day. In winter A. russatus showed no clearly detectable diurnal or ultradian rhythm in T b, which remained constant between narrow limits of 35.2 and 36.8°C.

SELECTION OF CITATIONS
SEARCH DETAIL
...